Enter your email address
Submit
Write your message
Fri, Jul 1, 2022
[Archive]
Volume 7, Issue 4 (July & August 2022)
J Obstet Gynecol Cancer Res 2022, 7(4): 356-357 |
Back to browse issues page
Download citation:
BibTeX | RIS | EndNote | Medlars | ProCite | Reference Manager | RefWorks
Send citation to:
BibTeX | RIS | EndNote | Medlars | ProCite | Reference Manager | RefWorks
Send citation to:
Hemida R. Misoprostol for Cervical Ripening Prior to Molar Evacuation: A letter to the editor. J Obstet Gynecol Cancer Res. 2022; 7 (4) :356-357
URL: http://jogcr.com/article-1-636-en.html
URL: http://jogcr.com/article-1-636-en.html
Professor of Obstetrics and Gynecology, North Africa representative of International Society of Study of Trophoblastic Diseases (ISSTD), Mansoura University, Mansoura, Egypt , redaelshouky@hotmail.com
Abstract: (606 Views)
Dear Editor- in –Chief of Journal of Obstetrics, Gynecology and Cancer Research (JOGCR),
I write to you regarding the published article in The Journal of Obstetrics, Gynecology, and Oncology research titled “The Association of Gestational Trophoblastic Neoplasia and Misoprostol Administered Before Suction Curettage of Molar Pregnancy” by Aminimoghaddam et al that was published on 27th of September, 2019 [1]. The article was revised with interest and raised for me some serious concerns.
Keywords: |Misoprostol|mola|evacuation|hazards. ,
Systematic Review: Letter to the Editor |
Subject:
Obstetrics and Gynecology
Received: 2022/02/3 | Accepted: 2022/03/1 | Published: 2022/03/14
Received: 2022/02/3 | Accepted: 2022/03/1 | Published: 2022/03/14
References
1. Aminimoghaddam S, Ahmad A, Bahman A, Nassiri S. The Association of Gestational Trophoblastic Neoplasia and Misoprostol Administered before Suction Curettage of Molar Pregnancy. J Obstet Gynecol Cancer Res. 2019; 4 (3) :111-116. [DOI:10.30699/jogcr.4.3.111]
2. Prata N, Weidert K. Efficacy of misoprostol for the treatment of postpartum hemorrhage: current knowledge and implications for health care planning. Int J Womens Health. 2016;8:341-349. [DOI:10.2147/IJWH.S89315] [PMID] [PMCID]
3. Leduc D, Biringer A, Lee L, Dy J, Clinical Practice Obstetrics C, Special C. Induction of labour. Journal of Obstetrics & Gynaecology Canada: JOGC. 2013;35(9):840-857. [DOI:10.1016/S1701-2163(15)30842-2]
4. Misoprostol: Drug information. In: Post WW, ed. UpToDate. Waltham (MA): UpToDate; 2018. Accessed 2018 Nov 22.
5. Allen R, O'Brien BM. Uses of misoprostol in obstetrics and gynecology. Rev Obstet Gynecol. 2009;2(3):159-168.
6. Royal College of Obstetricians and Gynaecologists. Developing a Green-top Guideline. London: RCOG; 2020.
7. Tidy J, Gillespie AM, Bright N, Radstone CR, Coleman RE, Hancock BW. Gestational trophoblastic disease: a study of mode of evacuation and subsequent need for treatment with chemotherapy. Gynecol Oncol 2000;78:309-12. [DOI:10.1006/gyno.2000.5839] [PMID]
8. Zakaria A, Hemida R, Elrefaie W, Refaie E. Incidence and outcome of gestational trophoblastic disease in lower Egypt. Afri Health Sci. 2020;20(1):73-82. [DOI:10.4314/ahs.v20i1.12] [PMID] [PMCID]
Send email to the article author
| Rights and permissions | |
 |
Journal of Obstetrics, Gynecology and Cancer Research by Farname Inc is licensed under a Creative Commons Attribution-NonCommercial 4.0 International License. Based on a work at http://jogcr.com/. |
Copyright Policy
Journal of Obstetrics, Gynecology and Cancer Research by Farname Inc is licensed under a Creative Commons Attribution-NonCommercial 4.0 International License.
Based on a work at http://jogcr.com/.
